{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T02:31:14Z","timestamp":1790217074240,"version":"4.1.0"},"reference-count":61,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,6,26]],"date-time":"2023-06-26T00:00:00Z","timestamp":1687737600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014942","name":"Novartis Gene Therapies","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014942","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","nmd-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuromuscular Disorders"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.nmd.2023.06.005","type":"journal-article","created":{"date-parts":[[2023,6,22]],"date-time":"2023-06-22T19:34:53Z","timestamp":1687462493000},"page":"670-676","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Onasemnogene abeparvovec preserves bulbar function in infants with presymptomatic spinal muscular atrophy: a post-hoc analysis of the SPR1NT trial"],"prefix":"10.1016","volume":"33","author":[{"given":"Richard D.","family":"Shell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katlyn E.","family":"McGrattan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Hurst-Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sally Dunaway","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Baranello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arseniy","family":"Lavrov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eamonn","family":"O'Brien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiri","family":"Wallach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"LaMarca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra P.","family":"Reyna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Basil T.","family":"Darras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nmd.2023.06.005_bib0001","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1097\/NEN.0000000000000144","article-title":"Spectrum of neuropathophysiology in spinal muscular atrophy type 1","volume":"74","author":"Harding","year":"2015","journal-title":"J Neuropathol Exp Neurol"},{"key":"10.1016\/j.nmd.2023.06.005_bib0002","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/0092-8674(95)90460-3","article-title":"Identification and characterization of a spinal muscular atrophy-determining gene","volume":"80","author":"Lefebvre","year":"1995","journal-title":"Cell"},{"key":"10.1016\/j.nmd.2023.06.005_bib0003","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.tins.2020.11.009","article-title":"Spinal muscular atrophy: in the challenge lies a solution","volume":"44","author":"Wirth","year":"2021","journal-title":"Trends Neurosci"},{"key":"10.1016\/j.nmd.2023.06.005_bib0004","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1038\/nrn2670","article-title":"Spinal muscular atrophy: why do low levels of SMN make motor neurons sick?","volume":"10","author":"Burghes","year":"2009","journal-title":"Nat Rev Neurosci"},{"key":"10.1016\/j.nmd.2023.06.005_bib0005","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.nmd.2018.01.003","article-title":"Correlation between SMA type and SMN2 copy number revisited: an analysis of 625 unrelated Spanish patients and a compilation of 2834 reported cases","volume":"28","author":"Calucho","year":"2018","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.nmd.2023.06.005_bib0006","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.nmd.2007.02.006","article-title":"The Hammersmith functional score correlates with the SMN2 copy number: a multicentric study","volume":"17","author":"Tiziano","year":"2007","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.nmd.2023.06.005_bib0007","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1007\/s00415-013-7154-1","article-title":"Mapping the differences in case for 5000 spinal muscular atrophy patients, a survey of 24 national registries in North America, Australasia, and Europe","volume":"261","author":"Bladen","year":"2014","journal-title":"J Neurol"},{"key":"10.1016\/j.nmd.2023.06.005_bib0008","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3389\/fmolb.2016.00007","article-title":"Copy number variations in the survival motor neuron genes: implications for spinal muscular atrophy and other neurodegenerative diseases","volume":"3","author":"Butchbach","year":"2016","journal-title":"Front Mol Biosci"},{"key":"10.1016\/j.nmd.2023.06.005_bib0009","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1212\/WNL.0000000000000741","article-title":"Observational study of spinal muscular atrophy type I and implications for clinical trials","volume":"83","author":"Finkel","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.nmd.2023.06.005_bib0010","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1002\/ana.25101","article-title":"Natural history of infantile-onset spinal muscular atrophy","volume":"82","author":"Kolb","year":"2017","journal-title":"Ann Neurol"},{"key":"10.1016\/j.nmd.2023.06.005_bib0011","doi-asserted-by":"crossref","first-page":"e696","DOI":"10.1212\/WNL.0000000000006050","article-title":"An observational study of functional abilities in infants, children, and adults with type 1 SMA","volume":"91","author":"Pane","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.nmd.2023.06.005_bib0012","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/1750-1172-6-71","article-title":"Spinal muscular atrophy","volume":"6","author":"D'Amico","year":"2011","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.nmd.2023.06.005_bib0013","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0201004","article-title":"Prospective and longitudinal natural history study of patients with type 2 and 3 spinal muscular atrophy: baseline data NatHis-SMA study","volume":"13","author":"Chabanon","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.nmd.2023.06.005_bib0014","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1212\/WNL.0b013e318271f7e4","article-title":"Prospective cohort study of spinal muscular atrophy types 2 and 3","volume":"79","author":"Kaufmann","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.nmd.2023.06.005_bib0015","doi-asserted-by":"crossref","first-page":"e587","DOI":"10.1212\/WNL.0000000000011051","article-title":"Respiratory trajectories in type 2 and 3 spinal muscular atrophy in the iSMAC cohort study","volume":"96","author":"Trucco","year":"2021","journal-title":"Neurology"},{"key":"10.1016\/j.nmd.2023.06.005_bib0016","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1002\/acn3.51281","article-title":"Natural history of type 2 and 3 spinal muscular atrophy: 2-year NatHis-SMA study","volume":"8","author":"Annoussamy","year":"2021","journal-title":"Ann Clin Transl Neurol"},{"key":"10.1016\/j.nmd.2023.06.005_bib0017","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s11689-021-09355-4","article-title":"Intellectual abilities, language comprehension, speech, and motor function in children with spinal muscular atrophy type 1","volume":"13","author":"Zappa","year":"2021","journal-title":"J Neurodev Disord"},{"key":"10.1016\/j.nmd.2023.06.005_bib0018","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.3390\/brainsci11091244","article-title":"Assessment of bulbar function in adult patients with 5q-SMA type 2 and 3 under treatment with nusinersen","volume":"11","author":"Brakemeier","year":"2021","journal-title":"Brain Sci"},{"key":"10.1016\/j.nmd.2023.06.005_bib0019","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1044\/2021_AJSLP-20-00217","article-title":"Dysphagia phenotypes in spinal muscular atrophy: the past, present, and promise for the future","volume":"30","author":"McGrattan","year":"2021","journal-title":"Am J Speech Lang Pathol"},{"key":"10.1016\/j.nmd.2023.06.005_bib0020","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1007\/s00455-021-10351-y","article-title":"Mastication in patients with spinal muscular atrophy types 2 and 3 is characterized by abnormal efficiency, reduced endurance, and fatigue","volume":"37","author":"van der Heul","year":"2022","journal-title":"Dysphagia"},{"key":"10.1016\/j.nmd.2023.06.005_bib0021","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/S1071-9091(98)80026-0","article-title":"Nutrition and swallowing in pediatric neuromuscular patients","volume":"5","author":"Tilton","year":"1998","journal-title":"Semin Pediatr Neurol"},{"key":"10.1016\/j.nmd.2023.06.005_bib0022","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1177\/0883073807305788","article-title":"Consensus statement for standard of care in spinal muscular atrophy","volume":"22","author":"Wang","year":"2007","journal-title":"J Child Neurol"},{"key":"10.1016\/j.nmd.2023.06.005_bib0023","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.ncl.2015.07.004","article-title":"Spinal muscular atrophy","volume":"33","author":"Kolb","year":"2015","journal-title":"Neurol Clin"},{"key":"10.1016\/j.nmd.2023.06.005_bib0024","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.nmd.2017.11.005","article-title":"Diagnosis and management of spinal muscular atrophy: part 1: recommendations for diagnosis, rehabilitation, orthopedic and nutritional care","volume":"28","author":"Mercuri","year":"2018","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.nmd.2023.06.005_bib0025","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.nmd.2017.11.004","article-title":"Diagnosis and management of spinal muscular atrophy: part 2: pulmonary and acute care; medications, supplements and immunizations; other organ systems; and ethics","volume":"28","author":"Finkel","year":"2018","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.nmd.2023.06.005_bib0026","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1706198","article-title":"Single-dose gene-replacement therapy for spinal muscular atrophy","volume":"377","author":"Mendell","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nmd.2023.06.005_bib0027","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S1474-4422(21)00001-6","article-title":"Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, multicentre, phase 3 trial","volume":"20","author":"Day","year":"2021","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.nmd.2023.06.005_bib0028","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/S1474-4422(21)00251-9","article-title":"Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): an open-label, single-arm, multicentre, phase 3 trial","volume":"20","author":"Mercuri","year":"2021","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.nmd.2023.06.005_bib0029","series-title":"Study of intrathecal administration of onasemnogene abeparvovec-xioi for spinal muscular atrophy (STRONG)","year":"2022"},{"key":"10.1016\/j.nmd.2023.06.005_bib0030","series-title":"Presented online at the 16th International Child Neurology Congress\/49th International Child Neurology Society 2020 Virtual Annual Meeting; October 12\u201320","article-title":"One-time administration of AVXS-101 IT for spinal muscular atrophy: phase I\/II study (STRONG)","author":"Finkel","year":"2020"},{"key":"10.1016\/j.nmd.2023.06.005_bib0031","series-title":"Efficacy and safety of intrathecal OAV101 (AVXS-101) in pediatric patients with type 2 spinal muscular atrophy (SMA) (STEER)","year":"2022"},{"key":"10.1016\/j.nmd.2023.06.005_bib0032","unstructured":"Lavrov A., Randazzo R., Segal F. Design and rationale of SMART, a Phase IIIb study evaluating intravenous onasemnogene abeparvovec in spinal muscular atrophy. Presented at the 3rd International Scientific Congress on Spinal Muscular Atrophy; Barcelona, Spain; October 21\u201323, 2022."},{"key":"10.1016\/j.nmd.2023.06.005_bib0033","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1038\/s41591-022-01866-4","article-title":"Onasemnogene abeparvovec for presymptomatic infants with two copies of SMN2 at risk for spinal muscular atrophy type 1: the phase III SPR1NT trial","volume":"28","author":"Strauss","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.nmd.2023.06.005_bib0034","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1038\/s41591-022-01867-3","article-title":"Onasemnogene abeparvovec for presymptomatic infants with three copies of SMN2 at risk for spinal muscular atrophy: the phase III SPR1NT trial","volume":"28","author":"Strauss","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.nmd.2023.06.005_bib0035","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3233\/JND-190424","article-title":"Advances in treatment of spinal muscular atrophy \u2013 new phenotypes, new challenges, new implications for care","volume":"7","author":"Schorling","year":"2020","journal-title":"J Neuromuscul Dis"},{"key":"10.1016\/j.nmd.2023.06.005_bib0036","series-title":"Poster presented at: Muscular Dystrophy Association Clinical & Scientific Congress","article-title":"Bulbar function in infants and children with spinal muscular atrophy type 1 following onasemnogene abeparvovec","author":"McGrattan","year":"2022"},{"key":"10.1016\/j.nmd.2023.06.005_bib0037","series-title":"Bayley Scales of Infant and Toddler Development","author":"Bayley","year":"2006"},{"key":"10.1016\/j.nmd.2023.06.005_bib0038","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1212\/WNL.0000000000002348","article-title":"Mandibular dysfunction as a reflection of bulbar involvement in SMA type 2 and 3","volume":"86","author":"van Bruggen","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.nmd.2023.06.005_bib0039","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1212\/WNL.0b013e3181c34aa6","article-title":"Dysphagia in spinal muscular atrophy type II: more than a bulbar problem?","volume":"73","author":"van den Engel-Hoek","year":"2009","journal-title":"Neurology"},{"key":"10.1016\/j.nmd.2023.06.005_bib0040","doi-asserted-by":"crossref","first-page":"361","DOI":"10.3233\/JND-190379","article-title":"Bulbar problems self-reported by children and adults with spinal muscular atrophy","volume":"6","author":"van der Heul","year":"2019","journal-title":"J Neuromuscul Dis"},{"key":"10.1016\/j.nmd.2023.06.005_bib0041","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1212\/WNL.0000000000000796","article-title":"Bulbar muscle MRI changes in patients with SMA with reduced mouth opening and dysphagia","volume":"83","author":"Wadman","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.nmd.2023.06.005_bib0042","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1080\/14656566.2019.1704732","article-title":"New treatments in spinal muscular atrophy: an overview of currently available data","volume":"21","author":"Ramdas","year":"2020","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.nmd.2023.06.005_bib0043","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","article-title":"Nusinersen versus sham control in infantile-onset spinal muscular atrophy","volume":"377","author":"Finkel","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nmd.2023.06.005_bib0044","doi-asserted-by":"crossref","first-page":"P1110","DOI":"10.1016\/S1474-4422(22)00339-8","article-title":"Safety and efficacy of risdiplam in patients with type 1 spinal muscular atrophy (FIREFISH part 2): secondary analyses from an open-label trial","volume":"21","author":"Masson","year":"2022","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.nmd.2023.06.005_bib0045","series-title":"Presented at the 43rd Annual Congress of the British Paediatric Neurology Association","article-title":"Primary efficacy and safety results from the Phase 3 ENDEAR study of nusinersen in infants diagnosed with spinal muscular atrophy","author":"Finkel","year":"2017"},{"key":"10.1016\/j.nmd.2023.06.005_bib0046","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.nmd.2019.09.007","article-title":"Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: interim efficacy and safety results from the phase 2 NURTURE study","volume":"29","author":"DeVivo","year":"2019","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.nmd.2023.06.005_bib0047","unstructured":"Servais L, Farrar MA, Vlodavets D, Zanoteli E, Al-Muhaizea M, Finkel RS, et\u00a0al. RAINBOWFISH: preliminary efficacy and safety data in risdiplam-treated infants with presymptomatic spinal muscular atrophy (SMA). Oral presentation presented at SMA Europe 2022, Barcelona, Spain; October 21\u201323, 2022. https:\/\/medically.gene.com\/content\/dam\/pdmahub\/restricted\/neurology\/sma-europe-2022\/SMA-EU-2022-presentation-servais-RAINBOWFISH-preliminary-efficacy-and-safety-data.pdf; 2022. [accessed November 29, 2022]."},{"key":"10.1016\/j.nmd.2023.06.005_bib0048","unstructured":"Swoboda KJ, Sansone VA, DeVivo DC, Bertini E, Hwu W-L, Makepeace C, et\u00a0al. Preserved swallowing function in infants who initiated nusinersen treatment in the presymptomatic stage of SMA: results from the NURTURE study. Abstract. Presented at 2021 MDA Virtual Clinical & Scientific Conference 2021. https:\/\/www.mdaconference.org\/abstract-library\/preserved-swallowing-function-in-infants-who-initiated-nusinersen-treatment-in-the-presymptomatic-stage-of-sma-results-from-the-nurture-study\/ [accessed February 8, 2023]."},{"key":"10.1016\/j.nmd.2023.06.005_bib0049","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.2147\/TCRM.S172291","article-title":"Clinical evidence supporting early treatment of patients with spinal muscular atrophy: current perspectives","volume":"15","author":"Dangouloff","year":"2019","journal-title":"Ther Clin Risk Manag"},{"key":"10.1016\/j.nmd.2023.06.005_bib0050","doi-asserted-by":"crossref","first-page":"5640","DOI":"10.3390\/ijerph17165640","article-title":"The economic impact and health-related quality of life of spinal muscular atrophy. An analysis across Europe","volume":"17","author":"Pe\u00f1a-Longobardo","year":"2020","journal-title":"Int J Environ Res Public Health"},{"key":"10.1016\/j.nmd.2023.06.005_bib0051","doi-asserted-by":"crossref","first-page":"106","DOI":"10.3389\/fneur.2019.00106","article-title":"Clinical measures of bulbar dysfunction in ALS","volume":"10","author":"Yunusova","year":"2019","journal-title":"Front Neurol"},{"key":"10.1016\/j.nmd.2023.06.005_bib0052","doi-asserted-by":"crossref","first-page":"8989","DOI":"10.3390\/ijerph17238989","article-title":"The burden of spinal muscular atrophy on informal caregivers","volume":"17","author":"Aranda-Reneo","year":"2020","journal-title":"Int J Environ Res Public Health"},{"key":"10.1016\/j.nmd.2023.06.005_bib0053","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.pedneo.2022.01.002","article-title":"Health-related quality of life in Thai children with spinal muscular atrophy","volume":"63","author":"Aksaralikitsunti","year":"2022","journal-title":"Pediatr Neonatol"},{"key":"10.1016\/j.nmd.2023.06.005_bib0054","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1186\/s12883-015-0473-3","article-title":"Understanding the experiences and needs of individuals with spinal muscular atrophy and their parents: a qualitative study","volume":"15","author":"Qian","year":"2015","journal-title":"BMC Neurol"},{"key":"10.1016\/j.nmd.2023.06.005_bib0055","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.nmd.2021.03.007","article-title":"Newborn screening programs for spinal muscular atrophy worldwide: where we stand and where to go","volume":"31","author":"Dangouloff","year":"2021","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.nmd.2023.06.005_bib0056","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1016\/j.jval.2022.06.010","article-title":"Cost-effectiveness of newborn screening for spinal muscular atrophy in the Netherlands","volume":"25","author":"Velikanova","year":"2022","journal-title":"Value Health"},{"key":"10.1016\/j.nmd.2023.06.005_bib0057","series-title":"Newborn screening for SMA","year":"2022"},{"key":"10.1016\/j.nmd.2023.06.005_bib0058","series-title":"Status of spinal muscular atrophy newborn screening in Europe","year":"2023"},{"key":"10.1016\/j.nmd.2023.06.005_bib0059","doi-asserted-by":"crossref","first-page":"139","DOI":"10.3389\/fneur.2020.00139","article-title":"The maximum bite force for treatment evaluation in severely affected adult SMA patients \u2013 protocol for a longitudinal study","volume":"11","author":"Kruse","year":"2020","journal-title":"Front Neurol"},{"key":"10.1016\/j.nmd.2023.06.005_bib0060","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/S0889-5406(99)70296-9","article-title":"Masticatory muscle function in patients with spinal muscular atrophy","volume":"115","author":"Granger","year":"1999","journal-title":"Am J Orthod Dentofacial Orthop"},{"key":"10.1016\/j.nmd.2023.06.005_bib0061","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.nmd.2017.05.011","article-title":"Spinal muscular atrophy: a changing phenotype beyond the clinical trials","volume":"27","author":"Tizzano","year":"2017","journal-title":"Neuromuscul Disord"}],"container-title":["Neuromuscular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960896623001530?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960896623001530?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T08:13:23Z","timestamp":1760775203000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960896623001530"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":61,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["S0960896623001530"],"URL":"https:\/\/doi.org\/10.1016\/j.nmd.2023.06.005","relation":{},"ISSN":["0960-8966"],"issn-type":[{"value":"0960-8966","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Onasemnogene abeparvovec preserves bulbar function in infants with presymptomatic spinal muscular atrophy: a post-hoc analysis of the SPR1NT trial","name":"articletitle","label":"Article Title"},{"value":"Neuromuscular Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nmd.2023.06.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}